What is Lunit?
Lunit is a specialized healthcare technology firm dedicated to conquering cancer through the application of artificial intelligence. The company develops sophisticated AI solutions designed for precision diagnostics and therapeutics, aiming to optimize the cost and accuracy of medical care. By focusing on the intersection of medical imaging and deep learning, Lunit provides clinicians with the tools necessary to identify the right diagnosis and determine the most effective treatment pathways for individual patients. Its market position is defined by a commitment to making data-driven medicine the new standard of care, effectively reducing the burden of cancer on global health systems.
How much funding has Lunit raised?
Lunit has raised a total of $307.5M across 5 funding rounds:
Series A
$3.5M
Series B
$15M
Series C
$78M
Other Financing Round
$61M
Other Financing Round
$150M
Series A (2016): $3.5M, investors not publicly disclosed
Series B (2018): $15M led by SOFTBANK Korea Co., Legend Capital, Capital Intervest, KT, Mirae Asset Global Investments, and Kakao Ventures
Series C (2021): $78M supported by Kakao Ventures, Guardant Health, Legend Capital, Shinhan Investment, IMM Investment, and InterVest
Other Financing Round (2021): $61M featuring HealthQuest Capital, Casdin Capital, and BrightEdge
Other Financing Round (2023): $150M, investors not publicly disclosed
Key Investors in Lunit
Kakao Ventures
A prominent venture capital firm that supports early-stage startups with high growth potential, focusing on technology-driven innovation across various sectors.
Guardant Health
A leading precision oncology company that provides comprehensive genomic testing and rare-cell diagnostics to help physicians identify personalized treatment alternatives for cancer patients.
Legend Capital
A long-standing private equity fund manager focused on innovation and growth enterprises, managing significant capital to support companies with strong operational potential.
What's next for Lunit?
With the recent influx of capital, Lunit is well-positioned to deepen its research and development efforts, particularly in the refinement of its diagnostic algorithms and the expansion of its therapeutic portfolio. The company is expected to prioritize the commercialization of its AI platforms in key global markets, fostering strategic partnerships with major healthcare providers and diagnostic laboratories. As Lunit transitions into its next phase of growth, the focus will likely shift toward regulatory scaling and the integration of its technology into routine clinical practice, ensuring that its precision medicine tools are accessible to a broader patient demographic while maintaining high standards of diagnostic efficacy.
See full Lunit company page
